Investigation of the effect of benign prostatic hyperplasia on body components via bioelectrical impedance analysis: a prospective study

Abstract

Objectives: The aim of this study was to investigate the effects of benign prostatic hyperplasia (BPH) on body composition using bioelectrical impedance analysis (BIA). Methods: This study was conducted prospectively in the Urology Clinic between May 1, 2015, and April 20, 2017. The BPH group included 310 patients aged 45–75 years diagnosed with BPH, without chronic disease and without surgery, while the control group included 270 patients in the same age range with urological diagnoses that did not affect BIA values. Prostate-specific antigen (PSA) levels for both groups were retrieved from medical records. Anthropometric measurements of body composition between the two groups were performed using the BIA-101 device (Akern Bioresearch Srl, Pontassieve, Florence, Italy). Data were analyzed between the two groups using Spearman’s correlation, independent samples t-test, Mann-Whitney U test, and logistic regression tests in IBM SPSS V22 software. Results: Body mass index (BMI), fat-free mass (FFM), body cell mass (BCM), muscle mass (MM), intracellular water (ICW), fat-free mass index (FFMI), and body cell mass index (BCM) were lower and statistically significant in the BPH group. Conversely, as expected, the PSA value was higher and statistically significant in the BPH group compared to the control group (p<0.001). In the age-adjusted logistic regression analysis, FFM was lower and statistically significant in the BPH group (p=0.038). Conclusion: The BIA method is a reliable, inexpensive, and easily applicable method that can be used to detect changes in body components of common diseases such as BPH.

Keywords

• anthropometry
• benign prostatic hyperplasia
• bioelectrical impedance analysis
• body mass index

References

1. Aaron L, Franco OE, Hayward SW. Review of prostate anatomy and embryology and the etiology of benign prostatic hyperplasia. Urol Clin North Am 2016;43:279–88.
2. Donovan JL, Kay HE, Peters TJ, Abrama P, Coast J, Matos-Ferreira A, Rentzhog L, Bosch JL, Nordling J, Gajewski JB, Barbalias G, Schick E, Silva MM, Nissenkorn I, de la Rosette JJ. Using the ICSQoL to measure the impact of lower urinary tract symptoms on quality of life: evidencefrom the ICS-’BPH’ study. International Continence Society - benign prostatic hyperplasia. Br J Urol 1997;80:712–21.
3. Negi SK, Desai S, Faujdar G, Jaiswal S, Sahu RD, Vyas N, Priyadarshi S. The correlation between obesity and prostate volume in patients with benign prostatic hyperplasia: a prospective cohort study. Urologia 2024;91:512–7.
4. Nian L, Shukang G, Shasha W, Xiangyun L. Aerobic exercises ameliorate benign prostatic hyperplasia via IGF-1/IGF-1R/ERK/AKT signalling pathway in prostate tissue of high-fat-diet-fed mice with insulin resistance. Steroids 2021;175:108910.
5. Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh Urology. 10th ed. Philadelphia (PA): Elsevier Saunders; 2012. p. 2533–610.
6. Bernoulli J, Yatkin E, Konkol Y, Talvitie EM, Santti R, Streng T. Prostatic inflammation and obstructive voiding in the adult Noble rat: impact of the testosterone to estradiol ratio in serum. Prostate 2008;68:1296–306.
7. Rundle A, Richards C, Neugut AI. Body composition, abdominal fat distribution, and prostate-specific antigen test results. Cancer Epidemiol Biomarkers Prev 2009;18:331–6.
8. Manav AN, Dündar M, Akdağ A. The use of prostate-specific antigen mass ratio in prostate cancer. Annals of Clinical Analytical Medicine 2022;13:606–10.

9. Rosa GB, Lukaski HC, Sardinha LB. The science of bioelectrical impedance-derived phase angle: insights from body composition in youth. Rev Endocr Metab Disord 2025;26:603–24.
10. Khalil SF, Mohktar MS, Ibrahim F. The theory and fundamentals of bioimpedance analysis in clinical status monitoring and diagnosis of diseases. Sensors (Basel) 2014;14:10895–928.
11. Karakaş S, Dişçigil G, Bilgin Md, Tekin N, Özlem S. Türkiye’den bir grup yaşlının antropometrik ölçümlerinin değerlendirilmesi. [Article in Turkish]. Turkish Journal of Geriatrics 2012;15:403–8.
12. Zhou Z, Liu G, Ji J, Liu Y, Liao L. Association of sarcopenic obesity with benign prostatic hyperplasia/lower urinary tract symptoms: a nationwide cross-sectional study. Eur Urol Open Sci 2025;82:81–7.
13. Wang H, Tang R, Hou H, Liu M, Wang Y, Wang J, Liu J, Wang J. Central obesity and its association with benign prostatic hyperplasia: insights from a cross-sectional study of NHANES 2001–2008. Aging Male 2025;28:2498943.
14. Alshahrani S. Modulating benign prostatic hyperplasia through physical activity-the emerging role of myokines: a narrative review. Medicina (Kaunas) 2025;61:1362.
15. Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, Landis P, Platz EA. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006;91:2562–8.
16. Çaşkurlu T, Akbulut ON, Arısan S, Çakır ÖO, Güney S, Ergenekon E. The role of obesity on BPH development. [Article in Turkish]. Türk Üroloji Dergisi 2004;30:224–9.
17. Daher M, Saqer T, Jabr M, Al-Mousa S. Benign prostatic hyperplasia and metabolic syndrome; prevalence and association: a cross-sectional study in Syria. BMC Urol 2023;23:187.
18. Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinccag N, Karsidag K, Genc S, Telci A, Canbaz B, Turker F, Yilmaz T, Cakir B, Tuomilehto J; TURDEP-II Study Group. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 2013;28:169–80.
19. Kyle, UG, Bosaeus I, Lorenzo AD, Deurenberg P, Elia M, Gomez JM, Heitmann BL, Kent-Smith L, Melchior JC, Pirlich M, Scharfetter H, Schols AM, Pichard C; Composition of the ESPEN Working Group. Bioelectrical impedance analysis – part I: review of principles and method. Clin Nutr 2004;23:1226–1243.